Dear Dr. Mary Black and Dr. Gunaretnam Rajagopal,

I am writing to strongly recommend my beloved student Mr. Shicheng Guo, who applied for the Principal Scientist Position at Janssen Pharmaceutica, Johnson & Johnson Company. Having been his supervisor for two years during 2013 to 2015 (exchange student program), I am proud to say that Mr. Guo is the best student I have ever taught and a truly exceptional young scientist. I believe that his creative research in human genetics, epigenetics and genetic epidemiology in biomedical research would help him to make great contribution to the novel drug development in this Principal Scientist Position.

Mr. Guo has received advanced education and training in the areas of genetics, molecular biology and genetic epidemiology. He received Bachelor degree in the Department of Biotechnology from the School of Life Science at the Northeast Agriculture University, Harbin, China in 2009, and then he was recommended into five year’s human medical genetics Ph.D program in Fudan University. Mr. Guo was an outstanding student. He made exceptional independent achievements. I am very impressed that although he took 30 courses in clinical research, bioinformatics and genetics, his GPA is still 3.37, which is very high quantile in Fudan University. I got to know Mr. Guo in a joint project for disease risk prediction models for thyroid cancer based on significant SNPs identified from GWAS study with his advisor Dr. Li Jin, vice president at the Fudan University, Shanghai, China, in 2011. His highly intelligence, diligence and perceptiveness really impressed me in the joint research. Recommended by his advisor, he came to Houston and joined the Ph. D program in biostatistics in the Division of Biostatistics, University of Texas School of Public Health, and then as my research assistant, he has focused on applying novel statistical methods for GWAS, RNA-seq and image-genetics data analysis which leverage high dimensional data reduction, causal inference and functional data analysis techniques to identify risk factors and predict diseases to make better understanding to the susceptibility and pathology of the complex diseases. He was supported by my grant: 5R01HL106034-02, “Statistical Methods for Finding Missing Heritability”.

As a Ph.D student, Mr. Guo is very promising. During his Ph.D studies he published 8 first or co-first authors in Journal of medical genetics, European Journal of Human Genetics, Genes and immunity and Clinical epigenetics. To my surprising, he published 4 Abstracts (Posters) in the International Meeting on Human Genome Variation and Complex Genome Analysis, Annual Meeting of American Society of Human Genetics, Epigenetics in Development and Diseases 9th Asian Epigenomics Meeting. He won the first place of poster award in the UT GSBS human and molecular genetics symposium in 2014 for his poster “Cluster analysis to RNA-seq data based on Function PCA reveals cancer subtype”.

Although great progress in genome-wide association studies (GWAS) has been made, the performance of the most current SNP- based disease risk prediction methods was not assessed accurately; He re-analyzed his previous published association data and evaluated the prediction ability with the significant SNPs which is identified by GWAS studies. Since thyroid is one of complex diseases with highest heritability among all the cancers, his result has an important implication that the role of the prediction ability based on few significant SNPs from GWAS study is limited. Also, this research re-emphasized that associations identified by GWAS account for only a few percent of the genetic variance, more attentions should be paid to the missing heritability caused by epigenetic variations such DNA methylation and histone modifications and temporal and spatial specific gene expression.

DNA methylation was suggested as the promising biomarker for early diagnosis of lung cancer. However, it is a great challenge to search for the optimized combination of the methylation biomarkers to obtain the maximum diagnosis performance. He developed a panel of DNA methylation biomarkers and validated their diagnostic efficiency for non-small cell lung cancer (NSCLC) in a large Chinese Han NSCLC retrospective cohort. Three high-throughput DNA methylation microarray datasets were collected in the discover stage. After normalization, batch effect elimination and integration, significant differential methylated genes and best combination of the biomarkers were determined with leave-one-out support vector machine (SVM) feature selection operation. Then candidate promoters were examined by methylation status determined single nucleotide primer extension technology (MSD-SNuPET) in an independent set of NSCLC/normal tissues. He proposed an effective DNA methylation-based biomarker discover pipeline and identified a promising panel for NSCLC diagnosis. High throughput DNA methylation microarray dataset followed by batch effect elimination can be a good method to discover optimized DNA methylation diagnostic panels. Methylation profiles of AGTR1, GALR1, SLC5A8, ZMYND10 and NTSR1, could be an effective assay for the NSCLC diagnosis. The works are prepared to be submitted to Genetics in Medicine. I fully believe that his works in these areas are of great importance and success.

RNA-seq technology provides huge biological information of gene expression and alternative splicing for biologist and medical scientists to discover diagnostic or prognostic biomarkers. Cumulative sum method was generally adopted in current RNA-seq analysis. However this analysis would ignore alternative splicing information which would play important role in the pathogenesis of the complex disease. He provided an effective novel pipeline to analysis of next-generation RNA-seq data based on Functional PCA which can identify aberrant alternative splicing in specific disease or conditions and can discover specific biological variation/subtype, such as cancer or normal, drug response status. This methodology takes the spatial information in the RNA expression characteristic into the consideration, which would be a great innovation in RNA-seq analysis and biological theoretical. The relevant works now have been accepted in Quantitative biology (2015) and PLoS One (2017).

As one of his supervisors, I have the highly priority to give Mr. Guo overall appraisals on his academic potentials and personalities. Mr. Guo has strong motivations in scientific research. He often presents me with creative ideas and has strong abilities to implement his ideas independently. Mr. Guo always can communicate effectively the concepts, approaches and significance of his research. Mr. Guo is polite and easy to work with collaborators. We have initiated extensive national and international collaboration, including scientists at the M.D. Anderson Cancer Center, Baylor College of Medicine, University of Texas Medical School, Yale University, University of Washington, and Beijing University, Fudan University in China. He was actively involved in these collaborative research projects. Particularly, he played an extremely important role in the project: “Point-of-Care Screening and diagnosis of liver cancer in Chinese Population” with Fudan University, Medical School of Nanjing University, and Fujian Medical University Union Hospital. He is an outstanding team Player. He is an intelligent, motivated and exceptional hard working researcher. He is consistent, dedicated and passionate, enthusiastic, cheerful, trustworthy and a pleasure to work with.

Actually, Dr. Guo have never stopped the collaboration with me in the past five years. Recently, he worked together with me on deep learning prediction of chemotherapy response using multi-omics features. His abstract have been accepted by ASHG 2019 as a poster presentation. In this study, he collected the chemotherapy and radiotherapy response information from 1,991 patients from TCGA project and predict the therapy response with conditional generative adversarial networks based deep learning approach and we found the prediction result is inspiring. I believe this project will be quite successful with further validation with the data from my lab.

In general, Mr. Guo is a very promising young scientist with multidisciplinary knowledge and skills in human genetics, clinical genomics and biomedical sciences. He has great motivation and outstanding ability to conduct both independent and collaborative research projects in clinical, epidemiological, genetic and epigenetic research, and cancer prevention. I strongly recommend him to be considered in the application to the Principal Scientist Position at Janssen Pharmaceutica, Johnson & Johnson Company, therefore, he can conduct and implement more original and competitive research in computational biology, multi-omics integrative analysis and novel drug identification based on genetic and epigenetics data. If you have any questions or wish to speak further about Mr. Guo, please feel free to call me or write me.

Sincerely Yours,

Momiao Xiong, Ph. D

Professor

Division of Biostatistics

Human Genetics Center

University of Texas School of Public Health

Phone: (713) 500-9894